News Results for IXICO (IXI)

Data analytics company Ixico swung to an annual profit as an increasing portfolio of clinical trial projects boosted services revenue. For the year ended September 30, the company reported a...

IXICO, the AI data analytics company delivering insights in neuroscience, will announce its final results for the year ended 30 September 2019 on 4 December 2019. At 8:12am: (LON:IXI) IXICO plc...

AI data analytics company Ixico said it had secured three new biopharma contracts and appointed Lammert Albers as chief business officer, effective immediately. The three new contracts included a...

Ixico said it expected top guidance and deliver its first full-year of positive earnings since going public thanks to accelerated revenue growth. For the year ended 30 September 2019, revenue...

UK stocks started the week on a bright note following advances on Asian exchanges with the benchmark FTSE 100 index closing up 1.1% at 7,195.6 Despite a downbeat Household Finance survey by...

UK stocks started the week on a bright note following advances on Asian exchanges, with mining companies leading substantial Monday morning gains. At 1230, the benchmark FTSE 100 index was up 1%...

UK stocks started the week on a bright note following advances on Asian exchanges, with mining companies leading substantial Monday morning gains. At 0831, the benchmark FTSE 100 index was up 65.4...

Data analytics company Ixico said it expected full-year revenue and earnings to be 'materially' ahead of market expectations amid strong growth in the second half of the year. 'Given the...

Data analytics company Ixico said it expected to meet market expectations for the current year and the next even as the company flagged a £3.5m loss in contract revenue after an existing client...

Charles Spicer, Chairman, bought 140,421 shares in the company on the 5th July 2019 at a price of 28.49p. The Director now holds 333,196 shares. NOTE: Aggregated price for several transactions on...

Data analytics company Ixico signed contracts with two biopharmaceutical companies to provide its technology-enabled imaging services to support an early phase study in Huntington's Disease and a...

Charles Spicer, Chairman, bought 70,175 shares in the company on the 18th March 2019 at a price of 28.50p. The Director now holds 192,775 shares. Story provided by StockMarketWire.com Director...

Giulio Cerroni, Chief Executive Officer, bought 53,300 shares in the company on the 12th March 2019 at a price of 28.00p. The Director now holds 84,850 shares. Story provided by...

Data analytics company IXICO said Friday it had been been chosen as partner in the newly established London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare. The...

Data analytics company Ixico on Thursday appointed Grant Nash as Chief Financial Officer. Mr Nash would take up the role on 29 April. He joined IXICO from the UK Biobank, a national and...

Ixico said Tuesday that Susan Lowther had resigned from her position as Chief Financial Officer to pursue other business interests. Until a successor is appointed, Conor Wolfson, who had been...

Data analytics company Ixico said Tuesday annual losses more than halved supported by strong revenue in its core imaging business. For the year ended 30 September 2018, pre-tax losses narrowed to...

Data science company Ixico said Thursday it had signed a further change order to a current contract with a biopharmaceutical company, increasing the total contract value to €1.3m. The latest...

Data science company Ixico said Tuesday it expected to report full-year performance ahead of market expectations. This upbeat outlook arrived as the company forecast reported revenue for the...

Data science company Ixico said Monday that it had signed an expanded scope to a current contract with a 'top 10' pharmaceutical company, increasing the value of the contract by £0.6m to £1.6m over...

Neuroscience-focused digital technology company Ixico said Tuesday one of its pharmaceutical clients would no longer require the company's imaging equipment after ending a phase II/III clinical...

Giulio Cerroni, Chief Executive Officer, bought 31,550 shares in the company on the 29th May 2018 at a price of 31.50p. The Director now holds 31,550 shares. Story provided by...

Charles Spicer, Chairman, bought 60,606 shares in the company on the 23rd May 2018 at a price of 33.00p. The Director now holds 122,684 shares. Story provided by StockMarketWire.com Director...

Digital technologies group Ixico operating losses more than halved in the six months to the end of March as revenue and margins grew. Operating losses after tax was £0.3m in the period, compared...

Ixico said Monday it signed a new contract with a top 10 pharmaceutical company, an existing client. The contract value is £1.0m over a three year term. Under the terms of the agreement, Ixico...

IXICO said Wednesday it has signed an extension to an existing contract with a top 15 global pharmaceutical company for advanced imaging clinical trial services in a neurodegenerative disease,...

Ixico said it had signed a new contract with an existing global pharmaceutical customer valued at $2.7m over a seven year term. Ixico would provide its technology enabled imaging services in a...

IXICO saw robust revenue growth in the year to the end of September strengthened by the entry into a number of new commercial contracts in a broad range of neurological diseases. The group said...

IXICO has signed a new contract with another leading biopharmaceutical company to support the use of wrist worn activity sensors ('wearable biosensors') in a late stage trial for a psychiatric...

IXICO has reported revenue for the year ended 30 September of £3.7m (2016: £3.1m). The Company said the £0.6m increase over the prior year reflects traction in the its commercially led organic...

IXICO has signed a new contract, with a top 15 global pharmaceutical company, utilising wrist worn activity sensors ('wearable biosensors') in a phase II clinical trial for a neurological...

IXICO, the digital technologies company serving neuroscience, has signed a new contract with a North American based biopharmaceutical company worth £1.2m over a three-year term. IXICO said it...

IXICO has signed an extension and expansion to its largest existing contract, which was awarded in August 2015, for a phase II/III clinical trial contract in Alzheimer's Disease. It said the...

Story provided by StockMarketWire.com

IXICO, the digital technologies company serving neuroscience, has expanded its pilot of the Assessa PML platform which includes Biogen, a leading company in Multiple Sclerosis, and expert reading...

Story provided by StockMarketWire.com

IXICO, the digital technologies company serving neuroscience, is holding an expert symposium today on the impact and future of imaging and digital biomarkers in Alzheimer's disease. The...

Story provided by StockMarketWire.com

The FTSE is rising in early deals with both the blue-chip and mid-cap indices making cautious headway in early deals as sterling fell on the dollar ahead of the anticipated UK services PMI for...

IXICO has signed a new contract for specialist imaging clinical trial services. It said the contract was for a phase II clinical trial of patients with mild cognitive impairment (MCI) due to...

Story provided by StockMarketWire.com

Operating losses at IXICO - the digital technologies company serving neuroscience - narrowed to £0.8m in the six months to the end of March from £1.1m last time. Revenue increased by 31% to £2.0m...

Story provided by StockMarketWire.com

IXICO, the brain health company, has signed a new contract worth US$1.5m for its imaging clinical trial technologies and services with an existing customer which is a top 10 pharmaceutical company....

IXICO has confirmed that Professor Derek Hill will present novel sleep measurement technology at a workshop on Mobile Devices for Clinical Trials in Neurological Diseases in Arizona, US. At...

IXICO, the brain health company, has appointed Giulio Cerroni as chief executive with effect from 6 February. He will take over from co-founder and current CEO Derek Hill, who will remain on the...

Story provided by StockMarketWire.com

IXICO, the brain health company, reports an operating loss of £2.9 million for the year to the end of September - up from £1.4m last time. Revenues were flat at £3.1 million and the group had...

Story provided by StockMarketWire.com

IXICO, the brain health company, is to take part in a new collaborative pan-European research effort under the Innovative Medicines Initiative's (IMI) umbrella focused on addressing the challenges...

Story provided by StockMarketWire.com

Brain health company IXICO has won a contract worth $1.2m with a top 15 global pharmaceutical company for advanced imaging clinical trial services in a rare neurodegenerative disease. The...

IXICOchief executive Derek Hill is giving an invited talk and joining an expert panel at The Coalition Against Major Diseases regulatory workshop in Washington today alongside representatives of...

Story provided by StockMarketWire.com

IXICO, the brain health company, has appointed Shore Capital and Corporate as nominated adviser and Shore Capital Stockbrokers as sole broker, with immediate effect. At 9:44am: (LON:IXI) IXICO...

IXICO non-executive chairman Dr Andy Richards has elected to step down from the board to focus on his other commitments. He has been chairman of IXICO since 2009 and has guided the company...

IXICO, the brain health company, has announced that Cygnus, a real world digital data collection study from people with cognitive impairment and dementia, has joined the high profile Dementias...

Story provided by StockMarketWire.com

IXICO, the brain health company, has strengthened its position in Parkinson's disease clinical trials. IXICO has joined seven global pharmaceutical companies including: AbbVie, AstraZeneca,...

Story provided by StockMarketWire.com

IXICO senior vice-president commercial operations, John Hall, and vice-president health technology, Ken Tubman, are delivering a presentation on Digital Biomarkers in Alzheimer's Disease at the...

IXICO, the brain health company, has been awarded a development contract by SBRI Healthcare (the Small Business Research Initiative for Healthcare) for the further development and integration of...

Story provided by StockMarketWire.com

The combined impact of dementia, age-related hearing and vision impairment is to be investigated by a new multi-million European research consortium led by the University of Manchester. Seven in...

Susan Lowther, Financial Director, bought 28,366 shares in the company on the 1st March 2016 at a price of 35.25p. The Director now holds 28,366 shares. Story provided by StockMarketWire.com...

Prof Derek Hill, Chief Executive Officer, bought 10,000 shares in the company on the 4th February 2016 at a price of 33.68p. The Director now holds 487,169 shares. Story provided by...

Dr Andy Richards, Chairman, bought 45,899 shares in the company on the 3rd February 2016 at a price of 32.68p. The Director now holds 76,099 shares. Story provided by StockMarketWire.com...

IXICO's strong performance in the year ended 30 September has continued, shareholders at the annual general meeting today will be told. Chairman Dr Andrew Richards will say: "The delivery of...

Story provided by StockMarketWire.com

IXICO, the brain health company, has been selected to participate in two of the NHS Innovation Test Beds, launched by NHS England Chief Executive Simon Stevens at the World Economic Forum in...

Story provided by StockMarketWire.com

MyBrainBook, IXICO's digital support platform for people with dementia and their carers, has won the Partnership with the NHS category in the SEHTA Regional Healthcare Business Awards. The award...

Story provided by StockMarketWire.com

IXICO has been awarded four new contracts with leading pharmaceutical companies and a specialist biotechnology company, with a combined value of over GBP3.0m. The contracts are for global...

Story provided by StockMarketWire.com

Ixico has narrowed its FY pretax loss to GBP1.4m, from a loss of GBP2.5m for the preceding 16-month period. Revenue was GBP3.1m, from GBP3.4m. "I am delighted to report growth in our clinical...

Story provided by StockMarketWire.com

IXICO, the brain health company, has entered into an agreement to conditionally acquire Optimal Medicine for the issue of up to £1.5m in consideration shares at an effective issue price of 49...

Story provided by StockMarketWire.com

IXICO, the brain health company, reports revenues for the year to the end of September of £3.1 million and other income at £1.0 million, in line with market expectations, giving combined total...

Story provided by StockMarketWire.com

IXICO, the brain health company, has been awarded a long-term contract from a leading global pharmaceutical company with a revenue value to IXICO of c. $1mper year. This project is for a large...

IXICO, together with its alliance partner, VirtualScopics, has been awarded contracts with two top 15 pharmaceutical companies, one in metastatic solid tumours and one in a rare neurodegenerative...

Story provided by StockMarketWire.com

IXICO, the brain health company, has released a beta version of MyBrainBook, its digital support platform for evaluation by people with dementia and their carers. MyBrainBook is being made...

Story provided by StockMarketWire.com

Brain health company IXICO posts a pre-tax loss of £772,000 for the six months to the end of March - down from £1.5m a year ago. Revenues rose to £1.6m from £1.2m and total operating expenses...

IXICO, the brain health company, has launched an Innovate UK grant funded project to support further development of its Assessa medical device technology. The project will develop digital...

Story provided by StockMarketWire.com

IXICO has launched a digital platform ('Project Cygnus') to support patients with the diseases that cause dementia. IXICO is the lead partner in the project, working alongside The Northern...

IXICO has been awarded a contract for a third clinical trial in Huntington's disease by a new US-based drug development speciality pharmaceutical customer. The contract is for an early phase...

Story provided by StockMarketWire.com

VirtualScopics, a leading provider of clinical trial imaging solutions, IXICO, the brain health company, and Micron, a provider of imaging services for clinical trials in Asia, have entered into a...

Story provided by StockMarketWire.com

Brain health company IXICO posts a net loss after tax of £2.3m for the 16 months to the end of September against to a net profit after tax of £0.5m for the year ended 31 May 2013. It says this...

Story provided by StockMarketWire.com

IXICO, the brain health company, has been selected as a partner within The European Prevention of Alzheimer's dementia Initiative (EPAD), a novel collaboration between academic and private sectors...

Story provided by StockMarketWire.com

IXICO, the brain health company, has signed a multi-year software licence and support agreement for its proprietary imaging data and query management digital platform, TrialTracker, with existing...